Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | TYMS | P04818 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29992857 | 1.00 | ALDH1A1 (0.39) | ALDH1A1HPGDMEN1LMNAKMT2A | |
| SCHEMBL6496327 | 0.81 | TP53 (0.44) | LMNASLC6A4MAOAMAPTCYP3A4 | |
| SCHEMBL12749869 | 0.78 | CYP3A4 (0.43) | ALDH1A1HPGDMEN1KMT2ASLC6A4 | |
| SCHEMBL709839 | 0.78 | MAPT (0.40) | ALDH1A1MEN1LMNAKMT2ASLC6A4 | |
| SCHEMBL3781466 | 0.78 | PDE7A (0.37) | ALDH1A1HPGDMEN1KMT2ASLC6A4 | |
| SCHEMBL1920608 | 0.77 | TYMS (0.37) | ALDH1A1HPGDMEN1LMNAKMT2A | |
| SCHEMBL30526797 | 0.77 | TYMS (0.37) | ALDH1A1HPGDMEN1LMNAKMT2A | |
| SCHEMBL5266532 | 0.76 | SLC6A4 (0.35) | SLC6A4MAOATYMSHTR2AHTR2C | |
| SCHEMBL2652648 | 0.76 | TSHR (0.41) | ALDH1A1HPGDMEN1KMT2ASLC6A4 | |
| SCHEMBL3723662 | 0.76 | HSD17B10 (0.50) | ALDH1A1HPGDMEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025037034-A1 | THIENOTHIADIAZINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2025-02-20 | — | — | WO | disclosed |
| EP-3510027-B1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | FGH BIOTECH INC (US) | 2022-11-02 | — | — | EP | disclosed |
| US-11339142-B2 | Di-substituted pyrazole compounds for the treatment of diseases | FGH BIOTECH, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| EP-3510027-A1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | FGH Biotech, Inc. (US) | 2019-07-17 | — | — | EP | disclosed |
| US-20190194167-A1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | FGH BIOTECH, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2018049080-A1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | FGH BIOTECH, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| WO-2018049080-A1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | FGH BIOTECH, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| EP-2938615-B1 | IMIDAZOPYRIDAZINE DERIVATIVES AS GABAA RECEPTOR MODULATORS | PFIZER LTD (GB) | 2016-10-26 | — | — | EP | disclosed |
| EP-2938615-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS GABAA RECEPTOR MODULATORS | Pfizer Limited (GB) | 2015-11-04 | — | — | EP | disclosed |
| US-20150259352-A1 | Chemical Compounds | PFIZER LTD (GB) | 2015-09-17 | — | — | US | disclosed |
| US-8124629-B2 | Naphthylacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124629-B2 | Naphthylacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124629-B2 | Naphthylacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2346807-A1 | NAPHTHYLACETIC ACIDS | F. Hoffmann-La Roche AG (CH) | 2011-07-27 | — | — | EP | disclosed |
| US-20100137250-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-06-03 | — | — | US | disclosed |
| US-20100137250-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-06-03 | — | — | US | disclosed |
| US-20100137250-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-06-03 | — | — | US | disclosed |
| WO-2010055005-A1 | NAPHTHYLACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010055005-A1 | NAPHTHYLACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | disclosed |
| US-20100069381-A1 | GSK-3BETAINHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339142-B2 | Di-substituted pyrazole compounds for the treatment of diseases | SREBF1, SREBF2, CYP27A1 | ALDH1A1 850/4885HPGD 782/4885MEN1 3569/4885 |
| US-20100069381-A1 | GSK-3BETAINHIBITOR | GSK3B, GSK3A, GSKIP | ALDH1A1 1473/4885HPGD 1023/4885MEN1 1680/4885 |
| US-20100137250-A1 | NAPHTHYLACETIC ACIDS | HRH2, HRH1, HRH3 | ALDH1A1 754/4885HPGD 366/4885MEN1 3010/4885 |
| US-20150259352-A1 | Chemical Compounds | GABRA5, GABRA4, GABRA3 | ALDH1A1 201/4885HPGD 848/4885MEN1 4364/4885 |
| US-20190194167-A1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | SREBF1, SREBF2, CYP27A1 | ALDH1A1 850/4885HPGD 782/4885MEN1 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.